Savings continue to grow with $408 billion saved in 2022 for the U.S. health care system, including patients, employers and taxpayers. Representing 90% of Rx filled but less than 18% of spending, generics and biosimilars are an integral part of the U.S. health care system.

Drug shortages, which hit crisis proportions between 2010 and 2011, can be a challenge for manufacturers, providers, and patients. Due to aggressive efforts by industry and the Food and Drug Administration (FDA), the incidence of shortages has declined, but recent reports suggest a rise in shortages in 2023.

We’re thrilled to announce that Dr. Robert Califf will be our keynote FDA speaker, joining us in-person for a special “Fireside Chat.” Don’t miss this opportunity to hear from top industry professionals and thought leaders!

The generic and biosimilar industry is working with Direct Relief to donate doses of medicines across the U.S. to people in need. You can be part of this collective effort by recording a short video on what you take for granted and sharing on social media with #4GRxANTED and @4GRxANTED.

A new report from AAM’s Biosimilars Council shows that even as patient demand for biosimilar insulin has grown dramatically, PBMs are continuing to restrict patient access and drive up drug prices.

Mark Cuban on generic medicines.

GRx+Biosims 2023 is the premier scientific & regulatory and policy event for the U.S. generics and biosimilars industry, featuring timely programming relevant to technical, regulatory and policy professionals. Top officials and subject-matter experts share their knowledge and best practices to enhance attendees' understanding of how to succeed in generic and biosimilar development, regulatory process and approvals, and the evolving policy landscape.

New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.

Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.